Circulating miRNA Expression Profiles and Machine Learning Models in Association with Response to Irinotecan-Based Treatment in Metastatic Colorectal Cancer

被引:9
|
作者
Pliakou, Evangelia [1 ]
Lampropoulou, Dimitra Ioanna [2 ]
Dovrolis, Nikolas [3 ]
Chrysikos, Dimosthenis [4 ]
Filippou, Dimitrios [5 ]
Papadimitriou, Christos [6 ]
Vezakis, Antonios [7 ]
Aravantinos, Gerasimos [1 ]
Gazouli, Maria [8 ]
机构
[1] Gen Oncol Hosp Kifissia Agioi Anargiroi, Dept Med Oncol 2, Nea Kifissia, Athens 14564, Greece
[2] ECONCARE, Athens 11528, Greece
[3] Democritus Univ Thrace, Dept Med, Lab Biol, Alexandroupolis 68100, Greece
[4] Natl & Kapodistrian Univ Athens, Hippoctat Hosp, Med Sch, Dept Propaedeut Surg 1, Athens 11528, Greece
[5] Natl & Kapodistrian Univ Athens, Med Sch, Dept Anat, Athens 11527, Greece
[6] Natl & Kapodistrian Univ Athens, Aretaie Hosp, Med Sch, Dept Surg 2, Athens 11528, Greece
[7] Natl & Kapodistrian Univ Athens, Aretaie Univ Hosp, Med Sch, Dept Surg, Athens 11528, Greece
[8] Natl & Kapodistrian Univ Athens, Med Sch, Dept Basic Med Sci, Lab Biol, Athens 11527, Greece
关键词
microRNAs; colorectal cancer; machine learning; artificial intelligence; irinotecan; resistance; DOWN-REGULATION; GASTRIC-CANCER; CELLS; ANGIOGENESIS; BEVACIZUMAB; MANAGEMENT; ONCOLOGY; SURVIVAL; GROWTH;
D O I
10.3390/ijms24010046
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer represents a leading cause of cancer-related morbidity and mortality. Despite improvements, chemotherapy remains the backbone of colorectal cancer treatment. The aim of this study is to investigate the variation of circulating microRNA expression profiles and the response to irinotecan-based treatment in metastatic colorectal cancer and to identify relevant target genes and molecular functions. Serum samples from 95 metastatic colorectal cancer patients were analyzed. The microRNA expression was tested with a NucleoSpin miRNA kit (Machnery-Nagel, Germany), and a machine learning approach was subsequently applied for microRNA profiling. The top 10 upregulated microRNAs in the non-responders group were hsa-miR-181b-5p, hsa-miR-10b-5p, hsa-let-7f-5p, hsa-miR-181a-5p, hsa-miR-181d-5p, hsa-miR-301a-3p, hsa-miR-92a-3p, hsa-miR-155-5p, hsa-miR-30c-5p, and hsa-let-7i-5p. Similarly, the top 10 downregulated microRNAs were hsa-let-7d-5p, hsa-let-7c-5p, hsa-miR-215-5p, hsa-miR-143-3p, hsa-let-7a-5p, hsa-miR-10a-5p, hsa-miR-142-5p, hsa-miR-148a-3p, hsa-miR-122-5p, and hsa-miR-17-5p. The upregulation of microRNAs in the miR-181 family and the downregulation of those in the let-7 family appear to be mostly involved with non-responsiveness to irinotecan-based treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer
    Heinemann, Volker
    Hoff, Paulo M.
    ONCOLOGY, 2010, 79 (1-2) : 118 - 128
  • [2] Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer
    Cha, Yongjun
    Kim, Sun Young
    Yeo, Hyun Yang
    Baek, Ji Yeon
    Choi, Moon Ki
    Jung, Kyung Hae
    Dong, Seung Myung
    Chang, Hee Jin
    NEOPLASIA, 2019, 21 (01): : 146 - 155
  • [3] Genomic alterations to predict response to irinotecan-based chemotherapy in metastatic colorectal cancer.
    De La Fouchardiere, Christelle
    Jiang, Xiaojun
    Pissaloux, Daniel
    Seigne, Christelle
    Wang, Qing
    Desseigne, Francoise
    Fondrevelle, Marie-Eve
    Cassier, Philippe Alexandre
    Attignon, Valery
    Combaret, Valerie
    Perol, David
    Tredan, Olivier
    Blay, Jean-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies
    Del Rio, M.
    Mollevi, C.
    Bibeau, F.
    Vie, N.
    Selves, J.
    Emile, J. -F.
    Roger, P.
    Gongora, C.
    Robert, J.
    Tubiana-Mathieu, N.
    Ychou, M.
    Martineau, P.
    EUROPEAN JOURNAL OF CANCER, 2017, 76 : 68 - 75
  • [5] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
    Alliot, C
    Barrios, M
    BRITISH JOURNAL OF CANCER, 2004, 90 (10) : 2050 - 2051
  • [6] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
    Aparicio, T
    Desramé, J
    Lecomte, T
    Mitry, E
    Belloc, J
    Etienney, I
    Montembault, S
    Vayre, L
    Locher, C
    Ezenfis, J
    Artru, P
    Mabro, M
    Dominguez, S
    BRITISH JOURNAL OF CANCER, 2003, 89 (08) : 1439 - 1444
  • [7] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
    T Aparicio
    J Desramé
    T Lecomte
    E Mitry
    J Belloc
    I Etienney
    S Montembault
    L Vayre
    C Locher
    J Ezenfis
    P Artru
    M Mabro
    S Dominguez
    British Journal of Cancer, 2003, 89 : 1439 - 1444
  • [8] Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
    Lucia Scarabel
    Marica Garziera
    Sara Fortuna
    Fioretta Asaro
    Giuseppe Toffoli
    Silvano Geremia
    Scientific Reports, 10
  • [9] Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
    Scarabel, Lucia
    Garziera, Marica
    Fortuna, Sara
    Asaro, Fioretta
    Toffoli, Giuseppe
    Geremia, Silvano
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [10] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
    C Alliot
    M Barrios
    British Journal of Cancer, 2004, 90 : 2050 - 2051